Anwendungsgebiet
Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated dose of metformin alone in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
In anderen Ländern
Dieselben Wirkstoffe in anderen Registern, dieselbe Marke zuerst.
Nationale Einträge
Die nationalen Register, in denen dieses EU-Arzneimittel aufgeführt ist.
- Segluromet 2,5 MG/1.000 MG Comprimidos Recubiertos con PeliculaSpanien · 3,238 mg + 1000 mgIm Handel
- Segluromet 7,5 MG/1.000 MG Comprimidos Recubiertos con PeliculaSpanien · 9,713 mg + 1000 mgZugelassen
- Segluromet 2,5 mg/1000 mg filmomhulde tablettenNiederlandeZugelassen
- Segluromet 2,5 mg/850 mg filmomhulde tabletten